MyFinsight
Home
Blog
About
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$94,714K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Stock-based compensation
Accounts payable and accrued exp...
Others
Negative Cash Flow Breakdown
Purchases of investment securiti...
Trade accounts receivable
Accretion of purchase discounts ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-120,855
-127,845
-122,815
-130,091
Stock-based compensation
24,881
29,680
21,720
22,702
Depreciation and amortization
1,073
1,160
994
1,012
Noncash lease expense
683
703
654
2,360
Accretion of purchase discounts and amortization of premiums on investment securities, net
2,023
2,220
2,734
12,691
Loss on equity method investment
-
-
0
0
Loss on disposal of property and equipment
0
-20
-8
0
Trade accounts receivable
6,274
5,091
592
-
Inventory
358
909
2,022
-
Prepaid expenses and other assets
463
7,024
-2,020
7,206
Accounts payable and accrued expenses, compensation and related expenses, and other liabilities
9,292
-12,064
11,176
6,647
Deferred revenue
516
-428
-707
-1,128
Operating lease liabilities
-665
-685
-603
-2,578
Net cash used in operating activities
-94,193
-124,703
-92,901
-110,718
Purchases of investment securities
155,211
554,428
213,646
216,700
Purchase of radionetics preferred stock
-
-
0
-
Proceeds from sales and maturities of investment securities
182,025
302,889
271,211
382,372
Purchases of property and equipment
521
820
458
863
Net cash used in investing activities
26,293
-252,359
57,107
164,809
Proceeds from issuance of common stock, net of commissions
0
380,514
0
0
Offering costs related to issuance of common stock
0
578
0
0
Proceeds from exercise of stock options and shares issued under employee stock purchase plan
-
-
40,611
-
Proceeds from exercise of stock options and shares issued under espp
8,925
-4,637
-
3,084
Net cash provided by financing activities
8,925
389,875
26,035
3,084
Net change in cash, cash equivalents and restricted cash
-58,975
12,813
-9,759
57,175
Exchange rate changes in cash, cash equivalents and restricted cash
132
-8
-106
-
Cash, cash equivalents and restricted cash - beginning of period
115,141
102,336
112,201
265,845
Cash, cash equivalents and restricted cash - end of period
56,298
115,141
102,336
112,201
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of investment...
$182,025K
(-65.69%↓ Y/Y)
Proceeds from exercise of
stock options and...
$8,925K
(-22.34%↓ Y/Y)
Net cash used in
investing activities
$26,293K
(154.77%↑ Y/Y)
Net cash provided by
financing activities
$8,925K
(-22.34%↓ Y/Y)
Canceled cashflow
$155,732K
Net change in cash,
cash equivalents and...
-$58,975K
(72.03%↑ Y/Y)
Canceled cashflow
$35,218K
Stock-based compensation
$24,881K
(-46.61%↓ Y/Y)
Accounts payable and
accrued expenses,...
$9,292K
(-16.74%↓ Y/Y)
Depreciation and
amortization
$1,073K
(-43.05%↓ Y/Y)
Noncash lease expense
$683K
(-57.45%↓ Y/Y)
Deferred revenue
$516K
(-47.56%↓ Y/Y)
Purchases of investment
securities
$155,211K
(-72.96%↓ Y/Y)
Purchases of property and
equipment
$521K
(-88.27%↓ Y/Y)
Net cash used in
operating activities
-$94,193K
(45.96%↑ Y/Y)
Canceled cashflow
$36,445K
Net loss
-$120,855K
(43.10%↑ Y/Y)
Trade accounts
receivable
$6,274K
Accretion of purchase
discounts and...
$2,023K
(-77.74%↓ Y/Y)
Operating lease
liabilities
-$665K
(62.77%↑ Y/Y)
Prepaid expenses and
other assets
$463K
(-95.91%↓ Y/Y)
Inventory
$358K
Buy us a coffee